Literature DB >> 16965182

Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.

Michael F Green1.   

Abstract

A considerable amount of evidence supports the relationship between cognitive impairment and functional outcomes in schizophrenia. Cognitive impairment is considered a core feature of schizophrenia that includes problems in speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. These deficits can also serve as an endophenotype for the illness in studies of genetics. Cognition is considered a reasonable treatment target in individuals with schizophrenia, partly because cognitive deficits contribute to poor functional outcomes. Similarly, evidence is beginning to emerge that cognitive impairment may also be a core feature of bipolar disorder. In addition, cognitive deficits adversely affect functional outcomes in bipolar disorder. This evidence suggests that cognition can be considered a reasonable target for intervention in both schizophrenia and bipolar disorder.

Entities:  

Mesh:

Year:  2006        PMID: 16965182

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  152 in total

1.  Reduced activity at the 5-HT(2C) receptor enhances reversal learning by decreasing the influence of previously non-rewarded associations.

Authors:  S R O Nilsson; T L Ripley; E M Somerville; P G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2012-05-29       Impact factor: 4.530

Review 2.  Evaluation of the clinical efficacy of asenapine in schizophrenia.

Authors:  Arpi Minassian; Jared W Young
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

Review 3.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

4.  Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats.

Authors:  M Ingallinesi; L Le Bouil; N Faucon Biguet; A Do Thi; C Mannoury la Cour; M J Millan; P Ravassard; J Mallet; R Meloni
Journal:  Mol Psychiatry       Date:  2014-08-26       Impact factor: 15.992

Review 5.  Animal models of bipolar mania: The past, present and future.

Authors:  R W Logan; C A McClung
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 6.  Neuromodulation of sleep rhythms in schizophrenia: Towards the rational design of non-invasive brain stimulation.

Authors:  Flavio Fröhlich; Caroline Lustenberger
Journal:  Schizophr Res       Date:  2020-04-27       Impact factor: 4.939

7.  Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Adam L Halberstadt; Xiaoxi Zhuang; Jared W Young
Journal:  J Affect Disord       Date:  2013-11-16       Impact factor: 4.839

8.  Multivariate Relationships Between Cognition and Brain Anatomy Across the Psychosis Spectrum.

Authors:  Amanda L Rodrigue; Jennifer E McDowell; Neeraj Tandon; Matcheri S Keshavan; Carol A Tamminga; Godfrey D Pearlson; John A Sweeney; Robert D Gibbons; Brett A Clementz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-03-31

9.  The impact of motivation on cognitive performance in an animal model of the negative and cognitive symptoms of schizophrenia.

Authors:  Ryan D Ward; Vanessa Winiger; Kerin K Higa; Julia B Kahn; Eric R Kandel; Peter D Balsam; Eleanor H Simpson
Journal:  Behav Neurosci       Date:  2015-04-27       Impact factor: 1.912

10.  Cognitive dysfunction with aging and the role of inflammation.

Authors:  Arthur A Simen; Kelly A Bordner; Mark P Martin; Lawrence A Moy; Lisa C Barry
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.